AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19562446 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 30
Study 17251214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin (titrated to 300 mg)
Number of subjects: 32
Study 17251214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (titrated to 320 mg)
Number of subjects: 32
Study 17251214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + parecoxib (40 mg)
Number of subjects: 32
Study 17251214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant + parecoxib (40 mg)
Number of subjects: 32
Study 17251214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15235348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyposis patients
Number of subjects: 50
Study 15235348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 11855527 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 0
Study 9603635 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (20 mg/kg t.i.d. i.v.)
Number of subjects: 185
Study 9603635 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (10-30 mg/kg t.i.d. i.v.)
Number of subjects: 185
Study 9603635 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 185
Study 9603635 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 185
Study 7802179 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G Whitacre needle
Number of subjects: 212
Study 7802179 — intervention group
Group type: COMPARATOR
Intervention: 27 G Whitacre needle
Number of subjects: 212
Study 3052815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrofenfluramine
Number of subjects: 43
Study 3052815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31305011 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 6051
Study 31305011 — intervention group
Group type: COMPARATOR
Intervention: Al(OH)3 (control)
Number of subjects: 6051
Study 25272321 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent abdominal pain (≥2/month)
Number of subjects: 420
Study 25272321 — intervention group
Group type: COMPARATOR
Intervention: Infrequent abdominal pain (<2/month)
Number of subjects: 420
Study 25272321 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 420
Study 25272321 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional overeating
Number of subjects: 420
Study 25272321 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental depression
Number of subjects: 420
Study 22973890 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care promoting problem-based learning programme (experimental group)
Number of subjects: 202
Study 22973890 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 202
Study 21732734 — intervention group
Group type: EXPERIMENTAL
Intervention: CranioSacral therapy (CST)
Number of subjects: 65
Study 21732734 — intervention group
Group type: COMPARATOR
Intervention: Low-strength static magnet (LSSM)
Number of subjects: 65
Study 19845810 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes intervention
Number of subjects: 20
Study 19845810 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group
Number of subjects: 20
Study 16753947 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg melatonin (Melaxen) daily at 22:30 h for 2 weeks
Number of subjects: 97
Study 16753947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 15774704 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Asians (Ko‐As)
Number of subjects: 88
Study 15774704 — intervention group
Group type: COMPARATOR
Intervention: Caucasians (Ca)
Number of subjects: 88
Study 12042193 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus 400 mg/day of celecoxib
Number of subjects: 50
Study 12042193 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 50
Study 9873970 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (25, 50, 75, or 100 micrograms) with bupivacaine 0.125%
Number of subjects: 100
Study 9873970 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (5, 10, 15, 20, or 25 micrograms) with bupivacaine 0.125%
Number of subjects: 100
Study 9873970 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.125% alone
Number of subjects: 100
Study 7840317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose arginine vasopressin (AVP) at rates of 500, 1,000, 2,000, and 4,000 microU.kg‐1.min‐1
Number of subjects: 18
Study 7840317 — intervention group
Group type: EXPERIMENTAL
Intervention: V1-receptor blockade during high-dose AVP
Number of subjects: 18
Study 7840317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose arginine vasopressin (AVP)
Number of subjects: 18
Study 7840317 — intervention group
Group type: COMPARATOR
Intervention: Plasma renin activity (PRA)
Number of subjects: 18
Study 1973907 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 micrograms)
Number of subjects: 13
Study 1973907 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 13
Study 1973907 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 13
Study 946580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cortisol (1,000 mg)
Number of subjects: 14
Study 946580 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular betamethasone (12.0 mg)
Number of subjects: 14
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers employed in painting industries
Number of subjects: 1999
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers employed in printing industries
Number of subjects: 1999
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers employed in painting and printing industries combined
Number of subjects: 1999
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers employed in painting industries
Number of subjects: 1999
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers employed in painting and printing industries combined
Number of subjects: 1999
Study 30838423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers employed in combined painting and printing industries
Number of subjects: 1999
Study 29035297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated Lumbar Extension (ILEX) resistance training for 12 weeks
Number of subjects: 77
Study 25110847 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 128
Study 25110847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication beliefs
Number of subjects: 128
Study 25110847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms
Number of subjects: 128
Study 25110847 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive medication beliefs
Number of subjects: 128
Study 25110847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 128
Study 24145618 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐month parent‐centred intervention involving self‐directed education provided in CD and DVD formats
Number of subjects: 146
Study 24145618 — intervention group
Group type: COMPARATOR
Intervention: Participant‐blinded control group who received generic nutrition and physical activity information
Number of subjects: 146
Study 21648282 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen + Calcium (G-III, n=22)
Number of subjects: 60
Study 21648282 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen (G-II, n=20)
Number of subjects: 60
Study 21648282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (G-I, n=18)
Number of subjects: 60
Study 19422580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site BB pacing
Number of subjects: 57
Study 19422580 — intervention group
Group type: EXPERIMENTAL
Intervention: RAA+CS pacing
Number of subjects: 57
Study 19422580 — intervention group
Group type: EXPERIMENTAL
Intervention: BB+CS pacing
Number of subjects: 57
Study 19422580 — intervention group
Group type: EXPERIMENTAL
Intervention: CS pacing
Number of subjects: 57
Study 19422580 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR)
Number of subjects: 57
Study 16898234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (13 weeks, at leisure time, in off‐worksite training facilities)
Number of subjects: 110
Study 16898234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 110
Study 15315591 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital thrombophilia
Number of subjects: 0
Study 15315591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antithrombotic treatment
Number of subjects: 0
Study 11231232 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 sutures
Number of subjects: 22
Study 11231232 — intervention group
Group type: COMPARATOR
Intervention: Metal staples
Number of subjects: 22
Study 9447569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761 (240 mg/day)
Number of subjects: 20
Study 9447569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8162662 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking one tobacco cigarette
Number of subjects: 85
Study 8162662 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 85
Study 3258200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polymyxin B for 5 days in addition to standard therapy
Number of subjects: 13
Study 3258200 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 13
Study 3258200 — intervention group
Group type: COMPARATOR
Intervention: Sera from burn patients
Number of subjects: 13
Study 3258200 — intervention group
Group type: COMPARATOR
Intervention: Affinity chromatography to remove endotoxin from sera
Number of subjects: 13
Study 31856812 — intervention group
Group type: EXPERIMENTAL
Intervention: App group (n = 100)
Number of subjects: 300
Study 31856812 — intervention group
Group type: EXPERIMENTAL
Intervention: App+Feedback group (n = 100)
Number of subjects: 300
Study 31856812 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (n = 100)
Number of subjects: 300
Study 28249254 — intervention group
Group type: EXPERIMENTAL
Intervention: ViE-coated polysulfone dialyzer
Number of subjects: 93
Study 28249254 — intervention group
Group type: COMPARATOR
Intervention: Low-flux synthetic dialyzer (Control)
Number of subjects: 93
Study 25418186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 666
Study 25418186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 666
Study 25418186 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 5 mg (withdrawal)
Number of subjects: 666
Study 25418186 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 10 mg (withdrawal)
Number of subjects: 666
Study 25418186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mg)
Number of subjects: 666
Study 25418186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mg)
Number of subjects: 666
Study 25418186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg (retreatment)
Number of subjects: 666
Study 25418186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg (retreatment)
Number of subjects: 666
Study 23280480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery with left atrial ablation
Number of subjects: 224
Study 23280480 — intervention group
Group type: COMPARATOR
Intervention: Cardiac surgery alone
Number of subjects: 224
Study 21567262 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy (group B)
Number of subjects: 40
Study 21567262 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (group A)
Number of subjects: 40
Study 18267029 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectation instructional set
Number of subjects: 60
Study 18267029 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectation instructional set
Number of subjects: 60
Study 18267029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral expectation instructional set
Number of subjects: 60
Study 16807257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 185
Study 16807257 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 185
Study 12971846 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional craniotomy
Number of subjects: 112
Study 12971846 — intervention group
Group type: COMPARATOR
Intervention: Puncture drainage and urokinase treatment
Number of subjects: 112
Study 11208407 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (2 mg i.v.)
Number of subjects: 53
Study 11208407 — intervention group
Group type: COMPARATOR
Intervention: Control (no clemastine)
Number of subjects: 53
Study 9410280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic stimulation in OSA patients (OSA-N)
Number of subjects: 37
Study 9410280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic stimulation in OSA patients (OSA-H)
Number of subjects: 37
Study 9410280 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxic stimulation in OSA patients (OSA-H)
Number of subjects: 37
Study 9410280 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxic stimulation in OSA patients (OSA-N)
Number of subjects: 37
Study 1611416 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CT
Number of subjects: 16
Study 1611416 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial CT
Number of subjects: 16
Study 1611416 — intervention group
Group type: COMPARATOR
Intervention: Plain radiography
Number of subjects: 16
Study 3903970 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxy-methyl-L-cysteine, 750 mg three times daily for three days before examination
Number of subjects: 103
Study 3903970 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 103
Study 31542565 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis® (internet-based intervention)
Number of subjects: 1013
Study 31542565 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1013
Study 29895874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intermittent theta-burst stimulation (iTBS) over the hand representation of the primary motor cortex, delivered in 10 sessions over a 2-week period.
Number of subjects: 12
Study 29895874 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta-burst stimulation (iTBS) over the hand representation of the primary motor cortex, delivered in 10 sessions over a 2-week period.
Number of subjects: 12
Study 27461586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam CT navigation
Number of subjects: 58
Study 27461586 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 58
Study 24840511 — intervention group
Group type: COMPARATOR
Intervention: sn-2 formula
Number of subjects: 300
Study 24840511 — intervention group
Group type: COMPARATOR
Intervention: sn-2+3 g/L OF
Number of subjects: 300
Study 24840511 — intervention group
Group type: COMPARATOR
Intervention: sn-2+5 g/L OF
Number of subjects: 300
Study 22607546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment (T)
Number of subjects: 120
Study 22607546 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tailored treatment (NT)
Number of subjects: 120
Study 22607546 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 120
Study 21033121 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for periarthritis of shoulder
Number of subjects: 120
Study 21033121 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for tennis elbow
Number of subjects: 120
Study 21033121 — intervention group
Group type: COMPARATOR
Intervention: Control group for periarthritis of shoulder
Number of subjects: 120
Study 21033121 — intervention group
Group type: COMPARATOR
Intervention: Control group for tennis elbow
Number of subjects: 120
Study 19016938 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) intervention
Number of subjects: 424
Study 19016938 — intervention group
Group type: COMPARATOR
Intervention: Successful aging (SA) health education intervention
Number of subjects: 424
Study 15750044 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose analysis of exhaled breath
Number of subjects: 59
Study 12584790 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI)
Number of subjects: 100
Study 12584790 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study 11853012 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline instillation prior to suctioning
Number of subjects: 17
Study 11853012 — intervention group
Group type: COMPARATOR
Intervention: No saline instillation prior to suctioning
Number of subjects: 17
Study 9130752 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass wool filtration
Number of subjects: 25
Study 9130752 — intervention group
Group type: COMPARATOR
Intervention: Percoll density gradient
Number of subjects: 25
Study 8213303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 3923
Study 3565663 — intervention group
Group type: EXPERIMENTAL
Intervention: Single mailed influenza vaccination cue
Number of subjects: 2217
Study 30032861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand files up to file 40/.02
Number of subjects: 58
Study 30032861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary files up to files 40/.04
Number of subjects: 58
Study 30032861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary files up to files 40/.06
Number of subjects: 58
Study 30032861 — intervention group
Group type: COMPARATOR
Intervention: Uninstrumented control group
Number of subjects: 58
Study 28860228 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior transversalis fascia approach
Number of subjects: 720
Study 28860228 — intervention group
Group type: COMPARATOR
Intervention: Preperitoneal space approach
Number of subjects: 720
Study 28860228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 720
Study 26444221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32 to 35°C) plus standard care
Number of subjects: 387
Study 26444221 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 387
Study 23192219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated to community-based outpatient treatment
Number of subjects: 160
Study 23192219 — intervention group
Group type: COMPARATOR
Intervention: Voluntary entry into treatment
Number of subjects: 160
Study 21245238 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 89
Study 21245238 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 89
Study 19256057 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial treatment plus wardenafil (10 mg in the evening)
Number of subjects: 103
Study 19256057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (fluoroquinolone + wardenafil)
Number of subjects: 103
Study 19256057 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacine (500 mg/day) monotherapy for 4 weeks
Number of subjects: 103
Study 16921688 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 96
Study 16921688 — intervention group
Group type: COMPARATOR
Intervention: Non-CUF (control)
Number of subjects: 96
Study 16921688 — intervention group
Group type: EXPERIMENTAL
Intervention: CUF
Number of subjects: 96
Study 16921688 — intervention group
Group type: EXPERIMENTAL
Intervention: CUF and Non-CUF
Number of subjects: 96
Study 12671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 52
Study 12671884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11192957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (1 mg b.d.)
Number of subjects: 321
Study 11192957 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg kg(‐1) day(‐1) for 4 days then 1 mg kg(‐1) day(‐1) for 3 days)
Number of subjects: 321
Study 9198507 — intervention group
Group type: EXPERIMENTAL
Intervention: No fluid or solids for at least four hours before the injection (Group A, 499 cases)
Number of subjects: 1000
Study 9198507 — intervention group
Group type: COMPARATOR
Intervention: Unlimited food and fluid (Group B, 501 cases)
Number of subjects: 1000
Study 1586386 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g omega‐3 fatty acids/day
Number of subjects: 48
Study 1586386 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.1 g omega‐3 fatty acids/day
Number of subjects: 48
Study 1586386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.6 g omega‐3 fatty acids/day
Number of subjects: 48
Study 1586386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29248101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted thrombolysis (USAT) catheter
Number of subjects: 80
Study 29248101 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter-directed thrombolysis (SCDT) catheter
Number of subjects: 80
Study 29248101 — intervention group
Group type: EXPERIMENTAL
Intervention: USAT catheter
Number of subjects: 80
Study 29248101 — intervention group
Group type: COMPARATOR
Intervention: SCDT catheter
Number of subjects: 80
Study 28510679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone (40 mg every 12 weeks for 2 years)
Number of subjects: 140
Study 28510679 — intervention group
Group type: COMPARATOR
Intervention: Saline (every 12 weeks for 2 years)
Number of subjects: 140
Study 26241420 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g plus 200 micrograms folic acid twice a day)
Number of subjects: 220
Study 26241420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 micrograms folic acid twice a day)
Number of subjects: 220